San Diego-based Accriva Diagnostics, a maker of point-of-care tests for strokes and other cardiovascular conditions, just raised about $15.5 million in equity, according to a regulatory filing.
It’s got a number of products – an anticoagulation monitoring system called Hemochron, a test that measures a patient’s platelet reactivity to antiplatelet meds, a heelstick device for newborns and several others. One of its devices, the InRhythm, isn’t yet FDA approved – the rest are.
Help employers find you! Check out all the jobs and post your resume.
It’s got a number of products – an anticoagulation monitoring system called Hemochron, a test that measures a patient’s platelet reactivity to antiplatelet meds, a heelstick device for newborns and several others. One of its devices, the InRhythm, isn’t yet FDA approved – the rest are.
Help employers find you! Check out all the jobs and post your resume.
